

# Alessandro Volpe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4640964/publications.pdf>

Version: 2024-02-01

34  
papers

802  
citations

567281

15  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1017  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. <i>Clinical Rheumatology</i> , 2022, 41, 3219-3225.	2.2	3
2	Practical approach to vasculitides in adults: an overview of clinical conditions that can mimic vasculitides closely. <i>Beyond Rheumatology</i> , 2020, 2, 3-13.	0.3	1
3	Vitamin D and autoimmune rheumatic diseases. <i>Clinical Rheumatology</i> , 2011, 30, 443-444.	2.2	4
4	Very low levels of vitamin D in systemic sclerosis patients. <i>Clinical Rheumatology</i> , 2010, 29, 1419-1425.	2.2	80
5	A study on thrombophilic factors in Italian Behcet's patients. <i>Joint Bone Spine</i> , 2010, 77, 330-334.	1.6	28
6	Étude des facteurs de thrombophilie chez les patients italiens atteints de maladie de Behçet. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 357-361.	0.0	1
7	Ultrasound evaluation of ulnar neuropathy at the elbow: correlation with electrophysiological studies. <i>Rheumatology</i> , 2009, 48, 1098-1101.	1.9	119
8	Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. <i>Joint Bone Spine</i> , 2009, 76, 333-342.	1.6	31
9	Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis. <i>Joint Bone Spine</i> , 2009, 76, 708-710.	1.6	44
10	Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. <i>Clinical Rheumatology</i> , 2009, 28, 391-395.	2.2	42
11	A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. <i>Clinical Rheumatology</i> , 2009, 28, 807-813.	2.2	39
12	Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. <i>Rheumatology International</i> , 2009, 29, 1073-1079.	3.0	12
13	Anti-TNFalpha, autoanticorps et maladies auto-immunes. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2009, 76, 616-625.	0.0	0
14	Dramatic progression of skin involvement in systemic sclerosis after the appearance of anti-Scl70 antibody: a case report. <i>Rheumatology International</i> , 2008, 28, 385-386.	3.0	2
15	Iloprost infusion does not reduce oxidative stress in systemic sclerosis. <i>Rheumatology International</i> , 2008, 28, 335-337.	3.0	5
16	Celiac disease in a rheumatology unit: a case study. <i>Rheumatology International</i> , 2008, 28, 547-551.	3.0	5
17	Hydroxychloroquine-induced DRESS syndrome. <i>Clinical Rheumatology</i> , 2008, 27, 537-539.	2.2	40
18	Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis. <i>Clinical Biochemistry</i> , 2007, 40, 837-842.	1.9	15

#	ARTICLE	IF	CITATIONS
19	B-flow ultrasound in a case of giant cell arteritis. <i>Clinical Rheumatology</i> , 2007, 26, 1955-1957.	2.2	6
20	Coexistence of systemic sclerosis with other autoimmune diseases. <i>Rheumatology International</i> , 2007, 27, 407-410.	3.0	44
21	Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. <i>Rheumatology International</i> , 2007, 27, 649-654.	3.0	15
22	Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature. <i>Clinical Rheumatology</i> , 2007, 26, 1795-1796.	2.2	12
23	Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. <i>Clinica Chimica Acta</i> , 2006, 364, 345-348.	1.1	36
24	Thyroid Status in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2006, 12, 322-324.	0.9	4
25	Plasma D-dimer concentration in patients with systemic sclerosis. <i>Thrombosis Journal</i> , 2006, 4, 2.	2.1	7
26	Évaluation de la température cutanée des patients atteints de sclérodémie traités périodiquement par iloprost. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2006, 73, 53-57.	0.0	1
27	Low levels of activated factor VII in systemic sclerosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 133-138.	2.1	0
28	Anti-TNF± therapy in rheumatoid arthritis and autoimmunity. <i>Rheumatology International</i> , 2006, 26, 209-214.	3.0	64
29	Psoriasis onset during infliximab treatment: description of two cases. <i>Rheumatology International</i> , 2006, 26, 1158-1160.	3.0	10
30	Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. <i>Rheumatology International</i> , 2006, 27, 203-205.	3.0	17
31	Evaluation of cardiac laboratory markers in patients with systemic sclerosis. <i>Clinical Biochemistry</i> , 2006, 39, 913-917.	1.9	50
32	Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost. <i>Joint Bone Spine</i> , 2006, 73, 57-61.	1.6	7
33	Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions. <i>Rheumatology International</i> , 2005, 25, 250-254.	3.0	6
34	Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. <i>Rheumatology International</i> , 2005, 26, 58-62.	3.0	52